Daré Bioscience (DARE) Set to Announce Quarterly Earnings on Tuesday

Daré Bioscience (NASDAQ:DARE) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 14th. Analysts expect Daré Bioscience to post earnings of ($0.06) per share for the quarter.

Daré Bioscience (NASDAQ:DARE) last posted its earnings results on Thursday, March 28th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.06. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $2.17 million. On average, analysts expect Daré Bioscience to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Daré Bioscience Stock Performance

DARE traded down $0.01 during trading on Wednesday, reaching $0.31. The stock had a trading volume of 27,221 shares, compared to its average volume of 569,581. The business has a 50-day moving average of $0.44 and a 200-day moving average of $0.38. The stock has a market cap of $30.68 million, a PE ratio of -0.91 and a beta of 1.31. Daré Bioscience has a one year low of $0.27 and a one year high of $1.06.

Analyst Ratings Changes

A number of brokerages have weighed in on DARE. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Daré Bioscience in a report on Wednesday, May 1st. Dawson James downgraded Daré Bioscience from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 30th. Finally, Brookline Capital Management cut shares of Daré Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, April 17th.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.